公开(公告)号：US20110129483A1

公开(公告)日：2011-06-02

申请号：US12735576

申请日：2009-01-29

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lioyd Old ,  Kenneth Lioyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lioyd Old ,  Kenneth Lioyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/13 ,  C12N1/21 ,  C12N1/19 ,  C12N5/07 ,  C12N5/04 ,  C07K14/435 ,  C07K7/08 ,  A61K39/00 ,  A61K38/00 ,  G01N33/53 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US09045533B2

公开(公告)日：2015-06-02

申请号：US14037504

申请日：2013-09-26

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C12P21/08 ,  C12N5/10 ,  C07K16/18 ,  C07K16/28 ,  C07K14/705 ,  C07K16/30 ,  A61K39/395 ,  C07K7/08 ,  C07K14/47 ,  A61K39/00

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US20160009816A1

公开(公告)日：2016-01-14

申请号：US14693261

申请日：2015-04-22

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/30 ,  A61K39/00 ,  G01N33/574 ,  C07K14/705

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本发明一般涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US08603474B2

公开(公告)日：2013-12-10

申请号：US12735576

申请日：2009-01-29

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： A61K39/395 ,  G01N33/53 ,  C07K16/00 ,  C07K16/28 ,  C07K16/18

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US20170362336A1

公开(公告)日：2017-12-21

申请号：US15609839

申请日：2017-05-31

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K39/395 ,  G01N33/574 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K7/08

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

公开(公告)号：US20140193417A1

公开(公告)日：2014-07-10

申请号：US14037504

申请日：2013-09-26

申请人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

发明人： Gerd Ritter ,  Beatrice Yin ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Kenneth Lloyd ,  Serhiy Souchelnytskiy ,  Ivan Gout ,  Valeriy Filonenko ,  Ramziya Kiyamova

IPC分类号： C07K16/18 ,  A61K39/00 ,  C07K7/08 ,  A61K39/395 ,  C07K14/47

CPC分类号： C07K16/3069 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/53 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/57449 ,  G01N2333/705 ,  G01N2500/04

摘要： The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

摘要翻译： 本公开总体上涉及作为治疗靶标的膜转运体NaPi2b（SLC34A2），包括免疫治疗，特别是癌症治疗。 包含SLC34A2的氨基酸312-340的SLC34A2表位肽已经使用单克隆抗体MX35鉴定为卵巢癌表位。 本发明还涉及SLC34A2和特别是SLC34A2肽在产生具有抗肿瘤或抗癌活性或刺激免疫应答的抗体中的用途。 本发明进一步涉及特异性针对NaPi2b（SLC34A2）和SLC34A2肽的抗体，包括贴面，嵌合，单链和人源化抗体。 还提供了产生免疫应答和治疗肿瘤和癌症的方法。 提供筛选和鉴定针对SLC34A2的化合物，包括SLC34A2表位肽和其他抗体的测定。

公开(公告)号：US20050158748A1

公开(公告)日：2005-07-21

申请号：US11004840

申请日：2004-12-07

申请人： Ivan Gout ,  Kenta Hara ,  Mike Waterfield ,  Kazu Yonezawa

发明人： Ivan Gout ,  Kenta Hara ,  Mike Waterfield ,  Kazu Yonezawa

IPC分类号： A61K38/00 ,  C12N9/12 ,  C12Q1/68 ,  C07H21/04 ,  C12N9/16

CPC分类号： C12N9/1205 ,  A61K38/00 ,  C07K2319/00

摘要： A novel S6 kinase, p70βS6k is described, along with methods of making and using p70βS6k protein and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70βS6k protein and/or its ligands.

摘要翻译： 描述了新型S6激酶，p70beta S6k，以及制备和使用p70beta S6k蛋白和相关核酸的方法。 本发明还公开了鉴定调节p70beta S6k蛋白和/或其配体的活性的试剂的方法。

公开(公告)号：US5846824A

公开(公告)日：1998-12-08

申请号：US780872

申请日：1997-01-09

申请人： Ian D. Hiles ,  Michael J. Fry ,  Ritu Dhand ,  Michael D. Waterfield ,  Peter J. Parker ,  Masayuki Otsu ,  George Panayoutou ,  Stefano Volinia ,  Ivan Gout

发明人： Ian D. Hiles ,  Michael J. Fry ,  Ritu Dhand ,  Michael D. Waterfield ,  Peter J. Parker ,  Masayuki Otsu ,  George Panayoutou ,  Stefano Volinia ,  Ivan Gout

IPC分类号： A61K38/00 ,  C12N9/12 ,  C12N5/10 ,  C12N5/16 ,  C12N15/54 ,  C12N15/63

CPC分类号： C12N9/12 ,  A61K38/00 ,  C12N2799/026

摘要： This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.

摘要翻译： 本发明涉及表现出激酶活性的新多肽，更具体地说，其表现出磷酸肌醇（PI）3-激酶活性。 这些多肽参与负责细胞生长和分化的途径。 公开了在昆虫细胞中通过重组生产产生时具有PI3-激酶活性的分离的多肽。

公开(公告)号：US20100247542A1

公开(公告)日：2010-09-30

申请号：US12598394

申请日：2008-05-01

申请人： Ivan Nemazanyy ,  Ganna Panasyuk ,  Alexander Zhyvoloup ,  Michael Waterfield ,  Ivan Gout

发明人： Ivan Nemazanyy ,  Ganna Panasyuk ,  Alexander Zhyvoloup ,  Michael Waterfield ,  Ivan Gout

IPC分类号： A61K39/395 ,  C07K14/435 ,  C12N15/12 ,  C12N15/63 ,  C12N5/07 ,  C07K16/00 ,  C12P21/00 ,  C12Q1/48 ,  C12Q1/68 ,  A61P35/00

CPC分类号： C12N9/12 ,  C07K14/4702 ,  C07K14/705 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/76 ,  C12P21/02 ,  C12Q1/485 ,  C12Q1/6876 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y207/11001 ,  G01N33/5008 ,  G01N2440/14

摘要： The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.

摘要翻译： 本发明涉及mTORbeta，mTOR的剪接形式，编码mTORβ的核酸和针对mTORβ的抗体。 本发明还涉及产生mTORβ的方法和筛选调节mTORβ表达和/或活性的试剂的方法。 本发明还涉及通过施用改变mTOR活性和/或表达的试剂来治疗与mTORβ异常表达相关的疾病的方法。

公开(公告)号：US07422849B1

公开(公告)日：2008-09-09

申请号：US09325095

申请日：1999-06-03

申请人： Ian D. Hiles ,  Michael J. Fry ,  Ritu Dhand ,  Michael D. Waterfield ,  Peter J. Parker ,  Masayuki Otsu ,  George Panayoutou ,  Stefano Volinia ,  Ivan Gout

发明人： Ian D. Hiles ,  Michael J. Fry ,  Ritu Dhand ,  Michael D. Waterfield ,  Peter J. Parker ,  Masayuki Otsu ,  George Panayoutou ,  Stefano Volinia ,  Ivan Gout

IPC分类号： C12Q1/00 ,  C12Q1/68 ,  G01N33/567 ,  C12P19/34 ,  C12N9/12

CPC分类号： C07K16/40 ,  A61K38/00 ,  C12N9/12 ,  C12P9/00

摘要： This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.

摘要翻译： 本发明涉及表现出激酶活性的新多肽，更具体地说，其表现出磷酸肌醇（PI）3-激酶活性。 这些多肽参与负责细胞生长和分化的途径。 公开了在昆虫细胞中通过重组生产产生时具有PI3-激酶活性的分离的多肽。